NCT04793997

Microbiome Therapy in Covid-19 Primary Care Support

Covid-19 Primary Care Support With Microbiome Therapy.

• Status: Suspended
• Phase: N/A
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: University Hospital, Antwerp · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This double-blind, randomized, placebo-controlled study aims to investigate whether a throat spray containing probiotic bacteria (i.e. microbiome spray) can reduce the symptoms and complaints of the SARS-CoV-2 virus in patients with mild to moderate symptoms. In addition, the aim is to investigate whether the microbiome spray can prevent transmission of the SARS-CoV-2 virus to household members.

Conditions

• SARS-CoV Infection
• Corona Virus Infection

Interventions

Type	Name	Description
BIOLOGICAL	Microbiome spray	Throat spray containing 3 beneficial lactobacilli strains
BIOLOGICAL	Placebo spray	Throat spray

Timeline

• Start date: 2021-02-01
• Primary completion: 2022-02-01
• Completion: 2022-02-01
• First posted: 2021-03-11
• Last updated: 2021-06-03

Locations

1 site across 1 country: Belgium